ASIA-PACIFIC DRY EYE DISEASE MARKET FORECAST 2024-2032

Japan, a leading country in healthcare innovation, demonstrates a high level of consistency, awareness, and commitment to healthcare improvements. According to two cross-sectional, population-based studies assessing the epidemiology of dry eye disease (DED), Japan had a higher prevalence of DED compared to other countries. Additionally, numerous studies have examined the economic impact of DED, showing that productivity losses per patient with confirmed DED ranged from $741 to $6,160, contributing to a significant economic burden. These factors, along with government support, research and development initiatives, and technological advancements, are expected to drive the demand for dry eye disease treatments in Japan.

In Indonesia, dry eye disease is commonly seen among the elderly, particularly those with cataracts. A study investigating the prevalence and subtypes of DED in the aging population prior to cataract surgery revealed that half of the participants experienced dry eye symptoms, classifying them as either having preclinical dry eye or DED, while over a quarter were identified as being at risk of developing the condition. 

The study underscores the prevalence of DED among older adults, who are increasingly susceptible to reduced tear production due to factors such as diminished corneal sensation, altered reflex secretion, lacrimal gland dysfunction, or inflammation-related damage to lacrimal glands. Furthermore, the role of oxidative stress and inflammation, which escalate with aging, is significant in the development of dry eye in the elderly. As a result, these factors are set to shape the landscape of the dry eye disease market in Indonesia.

The growing geriatric population in countries like Japan and South Korea is another significant driver of the market, as older individuals are more susceptible to age-related eye conditions. This, combined with an overall rise in healthcare awareness and access to diagnostic services, is boosting the market for treatment for dry eye disease across the region.

Innovations in dry eye disease treatment drugs and products are playing a crucial role in managing the condition. New therapies, such as eye drops for dry eye disease, as well as advancements in anti-inflammatory medications, are addressing patient needs more effectively. In addition, technological advancements in therapeutic and diagnostic products are enabling earlier and more accurate dry eye disease diagnosis, which is expected to drive treatment adoption across various markets in the region.

The Asia-Pacific dry eye disease market segmentation includes distribution channel, type, dosage, and product. The distribution channel segment is further divided into hospital pharmacies, online pharmacies/stores, and independent pharmacies and drugstores.

Online pharmacies have become a well-established distribution channel, gradually gaining acceptance in emerging markets while being thoroughly utilized in developed countries. The demand for a wide range of products available online has surged, driven by increased internet penetration. Consequently, the expansion of online services, the trend towards self-medication with over-the-counter products, and the growing use of the Internet have significantly boosted sales through online pharmacies. Additionally, rising awareness of primary care and prescription medications is expected to further drive growth in this segment.

Moreover, as healthcare technology advances, virtual healthcare is becoming increasingly popular, prompting pharmacies to enhance their online services. Most medications for dry eye disease are available as eye drops, which can conveniently be purchased online. Furthermore, during the pandemic, many consumers preferred using online pharmacies over visiting crowded physical stores, accelerating the shift towards digital pharmacy solutions.

Some of the leading companies operating in the Asia-Pacific dry eye disease market include Santen Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, etc.

Santen Pharmaceutical Co Ltd specializes in the marketing, manufacturing, and research & development of pharmaceutical products and medical devices. The company operates through its network of subsidiaries across the United States, Europe, and Asia. Its product portfolio includes prescription ophthalmic solutions for conditions such as glaucoma, diabetic retinopathy, myopia, dry eye, cataracts, and retinal detachment. Headquartered in Kita-ku, Osaka, Japan, Santen is a leading player in the ophthalmic sector. One of its notable products, IKERVIS®, is a treatment for severe keratitis in adults and contains the active ingredient ciclosporin.